Noom and Weightwatchers offer distinct behavioral frameworks for weight management—psychology-first vs. point-based systems—but neither replaces medical evaluation or medication therapy.

Noom and Hims are two distinct telehealth platforms offering GLP-1 medication programs, each with different business models, clinical oversight structures, and personalization strategies.

Noom emphasizes behavioral psychology and habit change through app-based coaching, while Remedy Meds centers on pharmacological interventions for weight loss. Each platform serves different preferences: psychology-first versus medication-supported approaches.

Noom emphasizes behavioral psychology and habit change through mobile coaching, while Mochi provides GLP-1 medication management via virtual care. Each serves different needs depending on clinical preference, genetics, and lifestyle readiness.

Noom emphasizes behavioral psychology and habit tracking, while Found specializes in GLP-1 medication management for weight loss.

Noom sells a behavior-change app and, separately, Noom Med, a clinician-led program that can include compounded GLP-1 medication. MEDVi is a medication-first telehealth program with coaching included. This comparison lines up the medication-inclusive tiers only, with prices from each company's own pages as of September 22, 2026.

Mochi and Noom are behavioral weight management apps that use different coaching models and AI-driven feedback. This comparison examines their clinical approaches, user experience, cost, and how they fit within a broader weight management strategy that may include pharmacological support.

Noom Legit is a behavioral weight-loss app combining psychology, nutrition coaching, and tracking tools. While evidence supports behavior modification, compounded GLP-1 medications may address metabolic factors that behavioral interventions alone cannot target.

Noom and Ro compared as two GLP-1 models — Noom app-first with a medication add-on, Ro telehealth-first with prescribing — covering structure, shared pharmacology, pricing to verify at the source, and the FTO genetics neither measures. PlexusDx is not affiliated with either.

This independent editorial review examines how Hers and Noom each build their GLP-1 weight programs, traces where the two telehealth models genuinely diverge in structure and dispensing, and highlights the pathway-level genetic context that neither brand reads before a prescription is ever written for you.

Noom pairs an app-based subscription with a medication add-on, and this independent review examines how tirzepatide fits that model — the compounded-versus-branded pathway, what moves the monthly cost, the SURMOUNT evidence, and the pathway-level genetics in FTO, MC4R and TCF7L2 that a telehealth intake never reads.

The cost of a program like Noom is rarely a single number. This independent review unpacks the pieces that build a monthly telehealth GLP-1 bill, contrasts cash-pay and membership structures, and explains why genetic pathway context is one input no fee schedule can capture.